ASH in 5 Minutes | Prof. An Gang: Immunotherapy Dominates MM Research, Exploration of Drug Resistance Mechanisms Vital

ASH in 5 Minutes | Prof. An Gang: Immunotherapy Dominates MM Research, Exploration of Drug Resistance Mechanisms Vital

2024.01.05
Currently, the highly anticipated 65th American Society of Hematology (ASH) Annual Meeting is underway in San Diego, USA. In the face of the annual pinnacle event in the field of hematologic malignancies, the front-line reporting team of "Hematology Frontier" delves deep, capturing the international cutting-edge developments and witnessing the outstanding performance of "China's good voice" on the global stage. In the realm of Multiple Myeloma (MM), advancements in targeted therapy and cell immunotherapy continue to dominate, making it imperative to comprehensively grasp the therapeutic progress at this year's ASH conference. "Hematology Frontier" had the privilege of interviewing Professor An Gang from the Hematology Hospital of the Chinese Academy of Medical Sciences, who brilliantly dissected the progress in MM.
BCMA/CD19 Dual-Target FasTCAR-T Cells Efficient and Safe in First-Line Treatment of High-Risk Newly Diagnosed Multiple Myeloma Patients

BCMA/CD19 Dual-Target FasTCAR-T Cells Efficient and Safe in First-Line Treatment of High-Risk Newly Diagnosed Multiple Myeloma Patients

2024.01.04
At the 65th American Society of Hematology Annual Meeting in 2023 (ASH), Professor Du Juan and her team from Shanghai Changzheng Hospital presented preliminary findings from a Phase I study (abstract 1022) assessing the efficacy and safety of BCMA/CD19 dual-target FasTCAR-T cells (GC012F) in treating high-risk, newly diagnosed multiple myeloma (HR-NDMM) patients. The study was selected for oral presentation at the conference. In this article, "Tumor Insight" has compiled the abstract content and invited Professor Du Juan to provide commentary for readers' reference.
ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression

ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression

2023.11.17
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Oncology Frontier team delved into the frontline, capturing international advancements and witnessing the strides made by China in the global oncology arena. Professor Changsong Qi from Peking University Cancer Hospital delivered a crucial oral presentation (Abstract No: 1018O) at this conference. In an exclusive interview with Oncology Frontier, Professor Qi shared insights from his reported research and thoughts on colorectal cancer studies presented at this year's ESMO. This article compiles relevant content for readers.
ESMO Highlights | Professor WeiYu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer

ESMO Highlights | Professor WeiYu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer

2023.11.17
 Bladder cancer is a common tumor in the urinary system, with muscle-invasive bladder cancer (MIBC) accounting for approximately 20% of all bladder cancers. Nearly half of non-muscle-invasive bladder cancer (NMIBC) patients may relapse into MIBC. Currently, various explorations in neoadjuvant therapy, including chemotherapy, immunotherapy, and their combination, have been conducted. The recent ESMO conference revealed several advancements in research. Professor Wei Yu from Peking University First Hospital shares the latest developments in neoadjuvant therapy and bladder preservation for bladder cancer.
ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

ESMO 2023 | Dr. Ryan J. Sullivan: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?

2023.11.13
The landscape of advanced melanoma treatment has witnessed a remarkable transformation with the introduction of targeted therapies and immunotherapies. While immunotherapy has shown great promise in various cancer types, there exist specific scenarios where targeted therapy can outshine immunotherapy. In this article, we delve into the situations where targeted therapy may be the preferred choice for advanced melanoma patients, while also examining the comparative efficacy and potential side effects of these treatment approaches.
Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

2023.10.13
The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of urothelial carcinoma (UC), significant progress has been made in research. Immunotherapy with immune checkpoint inhibitors (ICIs) in the first-line treatment for advanced UC, as reported in the final analysis of the IMvigor130 study, has provided more information on the population benefiting from immune therapy. Additionally, immunotherapy has expanded into early-stage treatment, with the updated 3-year follow-up data from the CheckMate 274 study showing a Disease-Free Survival (DFS) of up to 52.6 months in the PD-L1 > 1% subgroup. Furthermore, different targets such as Trop-2 and Nectin-4 in antibody-drug conjugates (ADCs) are being explored in various treatment modalities and are extending from later-line to first-line treatment.